Motif Neurotech: robotics company

Overview

Motif Neurotech is a Houston-based brain-computer interface company developing an implantable therapeutic BCI for treatment-resistant depression. Its Motif BCI XCS System is a wirelessly-powered implant delivering electrical stimulation to brain circuits linked to depression. FDA approved its first clinical trial (RESONATE) in April 2026, making Motif the fastest implantable BCI company from founding to IDE approval.

Verified record

Verified deployments: None on file
Active incidents: None on file

Key facts

FDA

IDE approved April 2026

Indication

Treatment-resistant depression

Program

ARPA-H behavioral health

Origin

Rice University research

Data & sources

Web sources

1

1 source backing this record.View all →

Models (1)

View all models →

Current platform

Motif BCI

Wirelessly powered implantable BCI delivering targeted brain stimulation for treatment-resistant depression.

biometricView model →

Motif Neurotech on the deployment map

View the global map

Motif Neurotech has no verified deployments on the DEPLOY registry yet. Explore the deployment map by place and type.

Free to use on your site, with a link back to DEPLOY.

The global deployment map →

No verified deployments for Motif Neurotech on the DEPLOY record yet. Track Motif Neurotech to know the moment the first one is verified.

Current leadership (2)

Sameer Sheth Co-foundersecondary-verified
Jacob Robinson CEO & Co-foundersecondary-verified

Safety record

No incidents on record for Motif Neurotech.

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Full safety record: incidents, sourcing, and exposure data →

Recent coverage

Motif Neurotech in third-party press

Motif Neurotech Receives FDA Approval to Begin First Clinical Trial of its Therapeutic BCI

Apr 27, 2026

Funding rounds (1)

Series A2024-01-24
$19M(reported)

See the full valuations ranking →

Recent activity

Every change to this record is dated, sourced, and independently verified where marked.

Record createdAug 8, 2026
Added to the verified registry

Full change history →

Sources (1)

https://news.rice.edu/news/2026/brain-computer-interface-based-rice-research-wins-fda-approval-first-clinical-trial

Common questions

What is Motif Neurotech?

Motif Neurotech is a Houston-based brain-computer interface company developing an implantable therapeutic BCI for treatment-resistant depression. Its Motif BCI XCS System is a wirelessly-powered implant delivering electrical stimulation to brain circuits linked to depression. FDA approved its first clinical trial (RESONATE) in April 2026, making Motif the fastest implantable BCI company from founding to IDE approval.

What does Motif Neurotech make?

Motif Neurotech has 1 robot model on the DEPLOY registry: Motif BCI (Motif Neurotech builds physical robots).

Who is the CEO of Motif Neurotech?

Jacob Robinson is the ceo of Motif Neurotech, per the DEPLOY registry.

Where is Motif Neurotech headquartered?

Motif Neurotech is headquartered in Houston, Texas, USA.

Where does Motif Neurotech operate robots?

Motif Neurotech is a robot manufacturer and does not directly operate deployments on the DEPLOY registry. Its products are deployed by customer operators; see the company page for the verified deployment record.

Is Motif Neurotech a top robotics company?

On DEPLOY's intelligence score, which blends verified deployments, funding, hiring, media, safety, and IP signals, Motif Neurotech ranks in roughly the top 90% of companies tracked by the registry.

When was Motif Neurotech founded?

Motif Neurotech was founded in 2022.

Is Motif Neurotech safe?

Motif Neurotech has no incidents on record in the DEPLOY registry. This does not constitute a safety guarantee; it reflects the incidents DEPLOY has tracked and verified to date.

Methodology: Verified · 1 source (no primary) · last reviewed 2026-08-08

Verification posture

Verified

Low confidence

Review state

Stable

Last reviewed 2026-08-08

Sources by quality tier

1: unclassified; Unclassified source

The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.

In the press

Recent coverage mentioning Motif Neurotech from third-party publications. Automatically surfaced; not part of the verified registry record.

Business WireApr 27, 2026

Motif Neurotech Receives FDA Approval to Begin First Clinical Trial of its Therapeutic BCI

FDA approved RESONATE trial at 8 institutions; Motif is fastest BCI company from founding to IDE approval (4 years)

↗

Machine-readable surfaces

Markdown mirror: /companies/motif-neurotech.md
RSS feed: /companies/motif-neurotech/feed.xml
JSON-LD: embedded in this page’s head
REST API: /v1/companies/0cd83b28-d0e9-4f17-be61-c9d20d2b618f
Revision history: /companies/motif-neurotech/history
Data documentation: /data
Query this programmatically: Deploy MCP

Reality vs attention

Motif Neurotech draws attention at the 8th percentile but verifies reality at the insufficient-data level among biometric robots.

RealityInsufficient datanot enough verified signal yet

Attention8thpctilemedia + video vs biometric robots

Compared to biometric robots →

Peer rankingTop 90% of Biometric

vs funding peers-14.5 ptsbelow funding-adj. expected

Open the Hype Gap chart →

Analysis

Limited public visibility and press coverage relative to peers.

Signal flags

Funding gap >24mo

Dimension breakdown

Verified signal

Insufficient data

26.0HIGH

Insufficient data

Insufficient data

Insufficient data

Attention (reach, not merit)

Market Presence →

1.2LOW

DEPLOY Intelligence scores are computed from verified registry data: confirmed deployments, disclosed funding rounds, regulatory filings, active job listings, video viewership, and press coverage. Confidence ratings reflect data availability. Scores update nightly.

DEPLOY Indices — verified vs claimed

Claim Integrity Fleet Reality Operator Repeat All indices

Last computed: Aug 9, 2026

Methodology Intelligence layer